keyword
MENU ▼
Read by QxMD icon Read
search

Chronic Heart failure treatment

keyword
https://www.readbyqxmd.com/read/29329993/pulmonary-arterial-hypertension-in-four-patients-treated-by-leflunomide
#1
Valentin Coirier, Alain Lescoat, Céline Chabanne, Maxime Fournet, Guillaume Coiffier, Stéphane Jouneau, Elisabeth Polard, Patrick Jégo
Pulmonary arterial hypertension (PAH) is a rare disorder that can be drug-induced, mostly following treatment by appetite-suppressant drugs. We report four cases of patients who developed PAH following a treatment by leflunomide for rheumatoid arthritis, psoriatic arthritis or undetermined connective tissue disease. All patients described a progressive dyspnea from grade II to IV of NYHA classification; clinical examination found signs of heart failure. PAH was finally diagnosed and confirmed by right heart catheterisation...
January 9, 2018: Joint, Bone, Spine: Revue du Rhumatisme
https://www.readbyqxmd.com/read/29325796/lcz696-sacubitril-valsartan-an-angiotensin-receptor-neprilysin-inhibitor-attenuates-cardiac-hypertrophy-fibrosis-and-vasculopathy-in-a-rat-model-of-chronic-kidney-disease
#2
Yasunori Suematsu, Wanghui Jing, Ane Nunes, Moti L Kashyap, Mahyar Khazaeli, Nosratola D Vaziri, Hamid Moradi
BACKGROUND: Chronic kidney disease (CKD) is associated with cardiac hypertrophy, fibrosis and increased risk of cardiovascular mortality. LCZ696 (Sacubitril/valsartan) is a promising agent which has shown significant potential in treatment of heart failure. We hypothesized that LCZ696 is more effective than valsartan alone in treatment of cardiovascular abnormalities associated with experimental CKD. METHODS AND RESULTS: Male Sprague Dawley rats underwent 5/6 nephrectomy and were subsequently randomized to no treatment (CKD), 30 mg/kg valsartan (VAL), or 60 mg/kg LCZ696 (LCZ)...
January 8, 2018: Journal of Cardiac Failure
https://www.readbyqxmd.com/read/29320517/explaining-the-decline-in-coronary-heart-disease-mortality-rates-in-the-slovak-republic-between-1993-2008
#3
Marek Psota, Piotr Bandosz, Eva Gonçalvesová, Mária Avdičová, Mária Bucek Pšenková, Martin Studenčan, Jarmila Pekarčíková, Simon Capewell, Martin O'Flaherty
OBJECTIVE: Between the years 1993 and 2008, mortality rates from coronary heart disease (CHD) in the Slovak Republic have decreased by almost one quarter. However, this was a smaller decline than in neighbouring countries. The aim of this modelling study was therefore to quantify the contributions of risk factor changes and the use of evidence-based medical therapies to the CHD mortality decline between 1993 and 2008. METHODS: We identified, obtained and scrutinised the data required for the model...
2018: PloS One
https://www.readbyqxmd.com/read/29319747/effect-of-an-orientation-group-for-patients-with-chronic-heart-failure-randomized-controlled-trial
#4
Cristina Silva Arruda, Juliana de Melo Vellozo Pereira, Lyvia da Silva Figueiredo, Bruna Dos Santos Scofano, Paula Vanessa Peclat Flores, Ana Carla Dantas Cavalcanti
OBJECTIVE: To evaluate the effect of the orientation group on therapeutic adherence and self-care among patients with chronic heart failure. METHOD: Randomized controlled trial with 27 patients with chronic heart failure. The intervention group received nursing consultations and participated in group meetings with the multi-professional team. The control group only received nursing consultations in a period of four months. Questionnaires validated for use in Brazil were applied in the beginning and in the end of the study to assess self-care outcomes and adherence to treatment...
January 8, 2018: Revista Latino-americana de Enfermagem
https://www.readbyqxmd.com/read/29318439/mind-the-gap-mismatches-between-clinicians-and-patients-in-heart-failure-medication-management
#5
Ken Lee Chin, Marina Skiba, Christopher M Reid, Andrew Tonkin, Ingrid Hopper, Justin A Mariani, Danny Liew
PURPOSE: Previous studies on the 'treatment gap' in patients with heart failure (HF) have focused either on prescribing or patients' adherence to prescribed treatment. This study sought to determine whether or not recent initiatives to close the gap have also minimised any mismatches between physicians' expectation of their patients' medications, medications in the patients' possession and their actual medication use. METHODS: A cross-sectional observational survey was conducted from December 2015 to June 2016 in The Alfred Hospital HF clinic in Melbourne, Australia...
January 9, 2018: Cardiovascular Drugs and Therapy
https://www.readbyqxmd.com/read/29312775/case-report-improvement-of-cardiac-remodeling-with-shock-wave-therapy-of-a-patient-with-ischemic-cardiomyopathy
#6
Yingnan Bai, Xiaoyan Wang, Xin Deng, Hongyi Wu, Abdel Hamid Fathy, Yan Xi, Yunzeng Zou, Jie Cui, Junbo Ge
Percutaneous coronary intervention (PCI) and coronary-artery bypass grafting (CABG) are two major preferred reperfusion strategies to restore the ischemic-related artery patency, but PCI and CABG do not necessarily guarantee the recovery of post-procedure left ventricular (LV) dysfunction and release of symptoms. Moreover, there is no definitive effective way to enhance microcirculations. Theoretically, shock wave therapy (SWT) is an option. We report here a case of patient who received SWT. The patient's medical history was characterized by chest pain for 20 years, having received CABG 13 years ago...
December 2017: Journal of Thoracic Disease
https://www.readbyqxmd.com/read/29306478/fibroblast-growth-factor-23-is-related-to-profiles-indicating-volume-overload-poor-therapy-optimization-and-prognosis-in-patients-with-new-onset-and-worsening-heart-failure
#7
Jozine M Ter Maaten, Adriaan A Voors, Kevin Damman, Peter van der Meer, Stefan D Anker, John G Cleland, Kenneth Dickstein, Gerasimos Filippatos, Pim van der Harst, Hans L Hillege, Chim C Lang, Marco Metra, Gerjan Navis, Leong Ng, Wouter Ouwerkerk, Piotr Ponikowski, Nilesh J Samani, Dirk J van Veldhuisen, Faiez Zannad, Aeilko H Zwinderman, Martin H de Borst
BACKGROUND: Fibroblast growth factor (FGF) 23 is a hormone that increases urinary phosphate excretion and regulates renal sodium reabsorption and plasma volume. We studied the role of plasma FGF23 in therapy optimization and outcomes in patients with new-onset and worsening heart failure (HF). METHODS: We measured plasma C-terminal FGF23 levels at baseline in 2399 of the 2516 patients included in the BIOlogy Study to Tailored Treatment in Chronic HF (BIOSTAT-CHF) trial...
February 15, 2018: International Journal of Cardiology
https://www.readbyqxmd.com/read/29305104/heart-failure-with-mid-range-ejection-fraction-in-patients-admitted-to-internal-medicine-departments-findings-from-the-rica-registry
#8
María Esther Guisado-Espartero, Prado Salamanca-Bautista, Óscar Aramburu-Bodas, Alicia Conde-Martel, José Luis Arias-Jiménez, Pau Llàcer-Iborra, Melitón Francisco Dávila-Ramos, Yolanda Cabanes-Hernández, Luis Manzano, Manuel Montero-Pérez-Barquero
AIM: To improve the knowledge on characteristics, treatment and prognosis in patients with heart failure (HF) and mid-range ejection fraction discharged after an acute HF episode. METHODS: We prospectively included and followed 2753 patients admitted with HF to Internal Medicine units. Patients were classified according to ejection fraction (EF) into three strata: reduced, EF <40% (HFrEF); mid-range EF 40-49% (HFmrEF); and preserved EF ≥50% (HFpEF). Clinical, echocardiographic, laboratory data and treatment at discharge were recorded and the groups were compared...
January 2, 2018: International Journal of Cardiology
https://www.readbyqxmd.com/read/29301869/astragaloside-iv-inhibits-ventricular-remodeling-and-improves-fatty-acid-utilization-in-rats-with-chronic-heart-failure
#9
Bin Tang, Jin-Guo Zhang, Hong-Yong Tan, Xi-Qing Wei
Chronic heart failure (CHF) is the end-stage of many cardiovascular diseases and severely affects the patients' lifespan. Inhibiting ventricular remodeling is thus a primary treatment target for CHF patients. Astragaloside IV (AS-IV) can improve cardiac function and protect myocardial cells. The study aims to investigate the effects of AS-IV on ventricular remodeling and explore its role in regulating energy metabolism using a rat CHF model. Sprague Dawley rats were divided into 5 groups (N=20 per group):  CHF + benazepril hydrochloride, CHF + low-dose (30 mg...
January 4, 2018: Bioscience Reports
https://www.readbyqxmd.com/read/29297189/are-changes-in-heart-rate-observed-during-dobutamine-stress-echocardiography-associated-with-a-response-to-cardiac-resynchronization-therapy-in-patients-with-severe-heart-failure-results-of-a-multicenter-viacrt-study
#10
Wojciech Gilewski, Jan Błażejewski, Danuta Karasek, Joanna Banach, Łukasz Wołowiec, Edyta Płońska-Gościniak, Tomasz Kukulski, Jarosław Kasprzak, Katarzyna Mizia-Stec, Ilona Kowalik, Piotr Gościniak, Władysław Sinkiewicz
BACKGROUND: According to current ESC Guidelines for the diagnosis and treatment of heart failure cardiac resynchronization therapy (CRT) is indicated in patients suffering from heart failure (HF) with reduced ejection fraction (EF) with significantly widened QRS complexes. Presence of vital myocardium proved by dobutamine stress echocardiography (DSE) is considered as a good prognostic factor for responsiveness to this treatment. Chronotropic incompetence is on the other hand known factor of unfavorable outcome in HF...
January 3, 2018: Kardiologia Polska
https://www.readbyqxmd.com/read/29297082/enhancing-recovery-from-sepsis-a-review
#11
REVIEW
Hallie C Prescott, Derek C Angus
Importance: Survival from sepsis has improved in recent years, resulting in an increasing number of patients who have survived sepsis treatment. Current sepsis guidelines do not provide guidance on posthospital care or recovery. Observations: Each year, more than 19 million individuals develop sepsis, defined as a life-threatening acute organ dysfunction secondary to infection. Approximately 14 million survive to hospital discharge and their prognosis varies. Half of patients recover, one-third die during the following year, and one-sixth have severe persistent impairments...
January 2, 2018: JAMA: the Journal of the American Medical Association
https://www.readbyqxmd.com/read/29297057/association-of-cardiovascular-risk-with-inhaled-long-acting-bronchodilators-in-patients-with-chronic-obstructive-pulmonary-disease-a-nested-case-control-study
#12
Meng-Ting Wang, Jun-Ting Liou, Chen Wei Lin, Chen-Liang Tsai, Yun-Han Wang, Yu-Juei Hsu, Jyun-Heng Lai
Importance: The associations between cardiovascular disease (CVD) and inhaled long-acting β2-agonists (LABAs) or long-acting antimuscarinic antagonists (LAMAs) in chronic obstructive pulmonary disease (COPD) are greatly debated. Pivotal and relevant randomized clinical trials included prior LABA or LAMA users and excluded patients with baseline CVD; therefore, cardiovascular events arising from first-time LABA or LAMA use, if any, could not be observed. There is an urgent need to examine whether new use of and duration since initiating LABAs and LAMAs could act as important determinants of cardiovascular events...
January 2, 2018: JAMA Internal Medicine
https://www.readbyqxmd.com/read/29287600/pulmonary-arterial-hypertension-in-a-patient-treated-with-dasatinib-a-case-report
#13
Andris Skride, Matiss Sablinskis, Kristaps Sablinskis, Krista Lesina, Aivars Lejnieks, Sandra Lejniece
BACKGROUND: There have been several reports on dasatinib-induced reversible pulmonary hypertension. This is the first reported case in Latvia; the patient did not discontinue the drug after the first adverse effects in the form of pleural effusions, which we speculate led only to partial reversion of the disease. CASE PRESENTATION: A 67-year-old white man with chronic myelogenous leukemia was treated with the dual Src and BCR-ABL tyrosine kinase inhibitor dasatinib...
December 29, 2017: Journal of Medical Case Reports
https://www.readbyqxmd.com/read/29286056/sacubitril-and-valsartan-fixed-combination-to-reduce-heart-failure-events-in-post-acute-myocardial-infarction-patients
#14
M Zaid Iskandar, C C Lang
Heart failure is a term used to define a constellation of symptoms and signs that are commonly attributed to the inability of the heart to produce a cardiac output that meets the demands of the body. It remains a deadly disease, affecting between 1-2% of the population, and is more common in the elderly, with around 6-10% of patients over 65 suffering from the condition. Sacubitril/valsartan (LCZ-696) is a combined neprilysin inhibitor and angiotensin AT1 receptor blocker approved in recent years for the treatment of chronic heart failure with reduced ejection fraction...
October 2017: Drugs of Today
https://www.readbyqxmd.com/read/29283405/the-impact-of-bronchodilator-therapy-on-systolic-heart-failure-with-concomitant-mild-to-moderate-copd
#15
Mahoto Kato, Kazuo Komamura, Masafumi Kitakaze, Atsushi Hirayama
In older adults, chronic obstructive pulmonary disease (COPD) is commonly associated with heart failure with reduced ejection fraction (HFrEF), and the high prevalence of this combination suggests that customized treatment is highly necessary in patients with COPD and HFrEF. To investigate whether the treatment of COPD with tiotropium, an anticholinergic bronchodilator, reduces the severity of heart failure in patients with HFrEF complicated by mild to moderate COPD, forty consecutive participants were randomly divided into two groups and enrolled in a crossover design study...
December 28, 2017: Diseases (Basel)
https://www.readbyqxmd.com/read/29283224/autonomic-regulation-therapy-to-enhance-myocardial-function-in-heart-failure-patients-the-anthem-hfpef-study
#16
Lorenzo A DiCarlo, Imad Libbus, H Uday Kumar, Sanjay Mittal, Rajendra K Premchand, Badri Amurthur, Bruce H KenKnight, Jeffrey L Ardell, Inder S Anand
BACKGROUND: Approximately half of the patients presenting with new-onset heart failure (HF) have HF with preserved left ventricular ejection fraction (HFpEF) and HF with mid-range left ventricular ejection fraction (HFmrEF). These patients have neurohormonal activation like that of HF with reduced ejection fraction; however, beta-blockers and angiotensin-converting enzyme inhibitors have not been shown to improve their outcomes, and current treatment for these patients is symptom based and empiric...
December 28, 2017: ESC Heart Failure
https://www.readbyqxmd.com/read/29283057/advanced-strategies-in-the-diagnosis-and-treatment-of-patients-with-coronary-artery-disease-and-heart-failure-when-heart-failure-causes-ischemia-and-angiotensin-converting-enzyme-inhibitor-and-betablockers-helps-in-diuresis
#17
Thach Nguyen, Nguyen Van Lanh, Vo Minh Viet, Lam Hoang Phuc, Trung N Pham, Khanh Duong, Luke Ashwin Lawrence, Vien T Truong, Gianluca Rigatelli
In the diagnosis and management of patients with coronary artery disease (CAD) and chronic left ventricular (LV) dysfunction or heart failure (HF), there are many uncertainties because of the non-specificity of the symptoms and signs of HF. Usually, severe CAD causes LV dysfunction. However, not rarely, LV dysfunction is the cause or aggravation of ischemia to many subsets of patients with or without CAD. In this article, the care of patients with CAD with LV dysfunction, along with the challenges of diagnosing asymptomatic HF and the criteria for monitoring success are presented...
December 27, 2017: Current Pharmaceutical Design
https://www.readbyqxmd.com/read/29281643/4-aminopyridyl-based-lead-compounds-targeting-cyp51-prevent-spontaneous-parasite-relapse-in-a-chronic-model-and-improve-cardiac-pathology-in-an-acute-model-of-trypanosoma-cruzi-infection
#18
Claudia Magalhaes Calvet, Jun Yong Choi, Diane Thomas, Brian Suzuki, Ken Hirata, Sharon Lostracco-Johnson, Liliane Batista de Mesquita, Alanderson Nogueira, Marcelo Meuser-Batista, Tatiana Araujo Silva, Jair Lage Siqueira-Neto, William R Roush, Mirian Claudia de Souza Pereira, James H McKerrow, Larissa M Podust
BACKGROUND: Chagas disease, caused by the protozoan Trypanosoma cruzi, is the leading cause of heart failure in Latin America. The clinical treatment of Chagas disease is limited to two 60 year-old drugs, nifurtimox and benznidazole, that have variable efficacy against different strains of the parasite and may lead to severe side effects. CYP51 is an enzyme in the sterol biosynthesis pathway that has been exploited for the development of therapeutics for fungal and parasitic infections...
December 2017: PLoS Neglected Tropical Diseases
https://www.readbyqxmd.com/read/29281158/treatment-outcomes-according-to-underlying-disease-in-pediatric-renovascular-hypertension
#19
Yeonhee Lee, Young Shin Lim, Sang Taek Lee, Heeyeon Cho
BACKGROUND: Renovascular hypertension (RVH) accounts for 5-10% of pediatric hypertension, and can be associated with underlying disease involving other organs. The purpose of this study was to evaluate the clinical characteristics and assess the treatment outcomes of Korean pediatric patients with RVH. METHODS: The medical records of 25 Korean pediatric patients with RVH were retrospectively reviewed. RESULTS: Twenty-four patients had underlying disease, and the most common cause was Moyamoya disease (MMD) (n = 10, 40%)...
December 27, 2017: Pediatrics International: Official Journal of the Japan Pediatric Society
https://www.readbyqxmd.com/read/29280914/anemia-and-coronary-artery-disease-pathophysiology-prognosis-and-treatment
#20
Jennifer A Rymer, Sunil V Rao
The mechanisms, pathophysiology, and treatment of anemia in coronary artery disease (CAD) are complex. The hemodynamic changes found in the acute anemic state may contribute to progressive arterial wall and left ventricular hypertrophy if the anemic state persists chronically. We will examine the evidence for anemia as an independent risk factor for CAD events and cardiovascular mortality after percutaneous coronary intervention. We will also investigate the thresholds for appropriate blood transfusion in patients with CAD, as well as the cardiovascular outcomes associated with the utilization of a liberal versus conservative blood transfusion strategy...
December 26, 2017: Coronary Artery Disease
keyword
keyword
114544
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"